Blueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses

Reuters06-13

Blueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses

Blueprint Medicines Corporation has announced the presentation of new data on the long-term clinical efficacy and safety profile of AYVAKIT®/AYVAKYT® (avapritinib) at the 2025 European Hematology Association (EHA2025) Hybrid Congress in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. These presentations, including one oral and two flash talks, highlight Blueprint Medicines' ongoing efforts to improve treatment for patients with systemic mastocytosis $(SM)$. The data underscore AYVAKIT's role as a durable standard of care for both indolent and advanced SM, and emphasize the real-world burden of the disease. The findings are based on patient data from the PIONEER, PATHFINDER, and EXPLORER trials, with follow-up extending up to five years for indolent SM and 6.5 years for advanced SM. The data presentations are available on the company's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blueprint Medicines Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NE09480) on June 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2543561528?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-13 06:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543561528","market":"nz","top_or_hot":-1,"title":"Blueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Blueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BPMC\">Blueprint Medicines Corporation</a> has announced the presentation of new data on the long-term clinical efficacy and safety profile of AYVAKIT®/AYVAKYT® (avapritinib) at the 2025 European Hematology Association (EHA2025) Hybrid Congress in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. These presentations, including one oral and two flash talks, highlight Blueprint Medicines' ongoing efforts to improve treatment for patients with systemic mastocytosis <a href=\"https://laohu8.com/S/SM\">$(SM)$</a>. The data underscore AYVAKIT's role as a durable standard of care for both indolent and advanced SM, and emphasize the real-world burden of the disease. The findings are based on patient data from the PIONEER, PATHFINDER, and EXPLORER trials, with follow-up extending up to five years for indolent SM and 6.5 years for advanced SM. The data presentations are available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blueprint Medicines Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NE09480) on June 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Blueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-13 06:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Blueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BPMC\">Blueprint Medicines Corporation</a> has announced the presentation of new data on the long-term clinical efficacy and safety profile of AYVAKIT®/AYVAKYT® (avapritinib) at the 2025 European Hematology Association (EHA2025) Hybrid Congress in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. These presentations, including one oral and two flash talks, highlight Blueprint Medicines' ongoing efforts to improve treatment for patients with systemic mastocytosis <a href=\"https://laohu8.com/S/SM\">$(SM)$</a>. The data underscore AYVAKIT's role as a durable standard of care for both indolent and advanced SM, and emphasize the real-world burden of the disease. The findings are based on patient data from the PIONEER, PATHFINDER, and EXPLORER trials, with follow-up extending up to five years for indolent SM and 6.5 years for advanced SM. The data presentations are available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blueprint Medicines Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NE09480) on June 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL90ggv7:1","article_id":"2543561528","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543561528","pubTimestamp":1749765696,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Blueprint Medicines Corporation has announced the presentation of new data on the long-term clinical efficacy and safety profile of AYVAKIT/AYVAKYT  at the 2025 European Hematology Association  Hybrid Congress in Milan, Italy, and the European Academy of Allergy and Clinical Immunology  Congress 2025 in Glasgow, United Kingdom. These presentations, including one oral and two flash talks, highlight Blueprint Medicines' ongoing efforts to improve treatment for patients with systemic mastocytosis . The data underscore AYVAKIT's role as a durable standard of care for both indolent and advanced SM, and emphasize the real-world burden of the disease. The findings are based on patient data from the PIONEER, PATHFINDER, and EXPLORER trials, with follow-up extending up to five years for indolent SM and 6.5 years for advanced SM. The data presentations are available on the company's website.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4505":"高瓴资本持仓","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BPMC":"Blueprint Medicines Corporation"},"translate_title":"Blueprint Medicines公布了AYVAKIT有希望的长期数据®2025年EHA和EAACI大会上的系统性肥大细胞增多症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BPMC":0.9},"content_text":"Blueprint Medicines Unveils Promising Long-Term Data for AYVAKIT® in Systemic Mastocytosis at 2025 EHA and EAACI Congresses\n    \n\nBlueprint Medicines Corporation has announced the presentation of new data on the long-term clinical efficacy and safety profile of AYVAKIT®/AYVAKYT® (avapritinib) at the 2025 European Hematology Association (EHA2025) Hybrid Congress in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, United Kingdom. These presentations, including one oral and two flash talks, highlight Blueprint Medicines' ongoing efforts to improve treatment for patients with systemic mastocytosis $(SM)$. The data underscore AYVAKIT's role as a durable standard of care for both indolent and advanced SM, and emphasize the real-world burden of the disease. The findings are based on patient data from the PIONEER, PATHFINDER, and EXPLORER trials, with follow-up extending up to five years for indolent SM and 6.5 years for advanced SM. The data presentations are available on the company's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blueprint Medicines Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NE09480) on June 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2543561528","isCrawlerRequest":true}